These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

714 related items for PubMed ID: 29036231

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats.
    Jin HY, Liu WJ, Park JH, Baek HS, Park TS.
    Arch Med Res; 2009 Oct; 40(7):536-44. PubMed ID: 20082866
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats.
    Ávila Dde L, Araújo GR, Silva M, Miranda PH, Diniz MF, Pedrosa ML, Silva ME, de Lima WG, Costa DC.
    Arch Med Res; 2013 Apr; 44(3):194-202. PubMed ID: 23523961
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.
    Miyagawa K, Kondo T, Goto R, Matsuyama R, Ono K, Kitano S, Kawasaki S, Igata M, Kawashima J, Matsumura T, Motoshima H, Araki E.
    Cardiovasc Diabetol; 2013 Nov 04; 12():160. PubMed ID: 24188631
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
    Yamaguchi M, Saji T, Mita S, Kulmatycki K, He YL, Furihata K, Sekiguchi K.
    Int J Clin Pharmacol Ther; 2013 Aug 04; 51(8):641-51. PubMed ID: 23782587
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
    Ahrén B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE.
    Diabetes Obes Metab; 2011 Sep 04; 13(9):775-83. PubMed ID: 21507182
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.
    Edgerton DS, Johnson KM, Neal DW, Scott M, Hobbs CH, Zhang X, Duttaroy A, Cherrington AD.
    Diabetes; 2009 Jan 04; 58(1):243-9. PubMed ID: 18840785
    [Abstract] [Full Text] [Related]

  • 17. Featured article: Structure moderation of gut microbiota in liraglutide-treated diabetic male rats.
    Zhang Q, Xiao X, Zheng J, Li M, Yu M, Ping F, Wang T, Wang X.
    Exp Biol Med (Maywood); 2018 Jan 04; 243(1):34-44. PubMed ID: 29171288
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R, Shikata K, Takatsuka T, Oda K, Miyamoto S, Kajitani N, Hirota D, Ono T, Usui HK, Makino H.
    Biochem Biophys Res Commun; 2014 Jan 17; 443(3):828-33. PubMed ID: 24342619
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.